Technology That Permits Focal Dose of Antibiotics to be Delivered to Lower Limb(s) of Diabetic Patients

Osprey Medical

Status and phase: Completed; Phase 2

Conditions: Infection; Diabetes

Treatments: Procedure: Percutaneous Isolated Limb Perfusion (PILP) delivery; Drug: Timentin

Study type: Interventional

Funder types: Industry

Identifiers

NCT02158442

O-PILP-C01 - Part B

Details and patient eligibility

About

The use of the Percutaneous Isolated Limb Procedure (PILP) which enables the use of existing antibiotic therapies in a more targeted and concentrated fashion in patients with diabetes who have a significant lower limb infection and it is deemed that IV antibiotics are needed in order to salvage the limb or life.

Full description

During the PILP procedure, the circulation of the limb is isolated separately from the general circulatory system thereby enabling the delivery of antibiotics only to the limb. Limb isolation is achieved by creating an "artificial" circuit where catheters are inserted into the major artery and vein of the lower limb.

Enrollment: 15 patients

Sex: All

Ages: 18 to 90 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• M or F subjects 18 - 90 years old
• Subject has pre-existing diabetes diagnosis
• Subject has significant infection below the ankle of soft tissue and may include bone, and IV antibiotics are needed in order to salve limb or life
• Consequence of infected wound would require Std of Care share debridement
• Subject willing and able to provide written informed consent
• Subject willing and able to comply with requirements of study protocol including pre-defined follow-up evaluations
• PROCEDURAL INCLUSION CRITERIA: successful cannulation of the femoral artery and vein and placement of the venous support device

Exclusion criteria

• Allergy to contrast media
• Known bleeding disorder including thrombocytopenia
• Recent AMI or elevated Troponin levels within last 30 days
• Penicillin sensitivity; Timentin sensitivity
• Female subjects known to be or suspected to be pregnant or lactating
• Subject unable to comply with instructions; especially to remain supine for duration of recirculation procedure
• Subjects who have participated in any other clinical trial or taken investigational drug within 30 days of study enrollment
• The PI determines the subject is not an appropriate subject for the study
• PROCEDURAL EXCLUSION CRITERIA: Subjects anatomy interferes with or is expected to prohibit successful cannulation of the femoral vessels or placement of the venous support device
• Known severe proximal femoral artery vascular disease precluding placement of perfusion catheters

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

15 participants in 2 patient groups

Treatment Group

Experimental group

Description:

The Treatment Group received intravenous Timentin prior to their PILP procedure.

Treatment:

Drug: Timentin

Procedure: Percutaneous Isolated Limb Perfusion (PILP) delivery

Control Group

Active Comparator group

Description:

The Control Group received standard dosings of intravenous Timentin plus other standard care.

Treatment:

Drug: Timentin